Study #2023-0090
ORB-011 in patients with advanced solid tumors
MD Anderson Study Status
Enrolling
Treatment Agent
ORB-011
Description
The goal of this clinical research study is to determine if an investigational new drug, named ORB-011, developed by Orionis Biosciences is safe and can be tolerated in people diagnosed with an advanced solid tumor. The study also aims to find the biologically optimal dose of the study medicine by assessing the safety and potential activity in the treatment of solid tumors. There are three phases to this study: screening, treatment and end of treatment.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Advanced Solid Cancer
Study phase:
Phase I
Physician name:
Apostolia Tsimberidou
Department:
Investigational Cancer Therapeutics
For general questions about clinical trials:
1-888-716-2090
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.